{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:42:48Z","timestamp":1771231368063,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-022-02396-1","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T22:02:48Z","timestamp":1657231368000},"page":"141-146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the effects of duloxetine treatment on anterior segment parameters by optical coherence tomography"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1807-6911","authenticated-orcid":false,"given":"Murat A.","family":"\u00d6zer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0127-6503","authenticated-orcid":false,"given":"\u0130lker F.","family":"Sar\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1241-1686","authenticated-orcid":false,"given":"Hakan","family":"Ko\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0122-6058","authenticated-orcid":false,"given":"Nur\u00e7e \u00c7.","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5166-6801","authenticated-orcid":false,"given":"Serkan","family":"\u00d6zen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0275-7093","authenticated-orcid":false,"given":"Faz\u0131l","family":"Kulakl\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"issue":"5","key":"2396_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2165\/11539240-000000000-00000","volume":"50","author":"MP Knadler","year":"2011","unstructured":"Knadler MP, Lobo E, Chappell J, Bergstrom R (2011) Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 50(5):281\u2013294. https:\/\/doi.org\/10.2165\/11539240-000000000-00000","journal-title":"Clin Pharmacokinet"},{"issue":"9\u201310","key":"2396_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.18071\/isz.70.0358","volume":"70","author":"A Mahmut","year":"2017","unstructured":"Mahmut A, Tunc V, Demiryurek E, Gursoy A (2017) Bilateral acute angle-closure glaucoma induced by\u00a0duloxetine. Ideggyogy Sz 70(9\u201310):358\u2013360. https:\/\/doi.org\/10.18071\/isz.70.0358","journal-title":"Ideggyogy Sz"},{"issue":"7","key":"2396_CR3","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1177\/1060028014529645","volume":"48","author":"AS Shifera","year":"2014","unstructured":"Shifera AS, Leoncavallo A, Sherwood M (2014) Probable association of an attack of bilateral acute angle-closure glaucoma with duloxetine. Ann Pharmacother 48(7):936\u2013939. https:\/\/doi.org\/10.1177\/1060028014529645","journal-title":"Ann Pharmacother"},{"issue":"6","key":"2396_CR4","doi-asserted-by":"publisher","first-page":"e692","DOI":"10.4088\/JCP.15m10038","volume":"77","author":"HY Chen","year":"2016","unstructured":"Chen HY, Lin CL, Lai SW, Kao CH (2016) Association of selective serotonin reuptake inhibitor use and acute angle-closure glaucoma. J Clin Psychiatry 77(6):e692\u2013e696. https:\/\/doi.org\/10.4088\/JCP.15m10038","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"2396_CR5","doi-asserted-by":"publisher","first-page":"575.e1","DOI":"10.1016\/j.genhosppsych.2012.09.001","volume":"35","author":"HY Ho","year":"2013","unstructured":"Ho HY, Kam KW, Young AL, Chan LK, Yu EC (2013) Acute angle closure glaucoma after sertraline. Gen Hosp Psychiatry 35(5):575.e1\u20132. https:\/\/doi.org\/10.1016\/j.genhosppsych.2012.09.001","journal-title":"Gen Hosp Psychiatry"},{"issue":"10","key":"2396_CR6","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/gps.4327","volume":"30","author":"A Achiron","year":"2015","unstructured":"Achiron A, Aviv U, Mendel L, Burgansky-Eliash Z (2015) Acute angle closure glaucoma precipitated by olanzapine. Int J Geriatr Psychiatry 30(10):1101\u20131102. https:\/\/doi.org\/10.1002\/gps.4327","journal-title":"Int J Geriatr Psychiatry"},{"issue":"9","key":"2396_CR7","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/bjophthalmol-2017-311529","volume":"102","author":"HG Zhang","year":"2018","unstructured":"Zhang HG, Ying GS (2018) Statistical approaches in published ophthalmic clinical science papers: a comparison to statistical practise two decades ago. Br J Ophthalmol 102(9):1188\u20131191. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311529","journal-title":"Br J Ophthalmol"},{"key":"2396_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/JCP.0b013e31825420a1","volume":"32","author":"DP Seitz","year":"2012","unstructured":"Seitz DP, Campbell RJ, Bell CM et al (2012) Short-term exposure to antidepressant drugs and risk of acute angle-closure glaucoma in older adults. J Clin Psychopharmacol 32:403\u2013407. https:\/\/doi.org\/10.1097\/JCP.0b013e31825420a1","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"2396_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2165\/00023210-200418080-00001","volume":"18","author":"C Costagliola","year":"2004","unstructured":"Costagliola C, Parmeggiani F, Sebastiani A (2004) SSRIs and intraocular pressure modifications: evidence, therapeutic implications and possible mechanisms. CNS Drugs 18(8):475\u2013484. https:\/\/doi.org\/10.2165\/00023210-200418080-00001","journal-title":"CNS Drugs"},{"issue":"12","key":"2396_CR10","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.4103\/0366-6999.233952","volume":"131","author":"N Zhou","year":"2018","unstructured":"Zhou N, Zhao JX, Zhu YN, Zhang P, Zuo Y (2018) Acute angle-closure glaucoma caused by venlafaxine. Chin Med J (Engl) 131(12):1502\u20131503. https:\/\/doi.org\/10.4103\/0366-6999.233952","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"2396_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/sj.eye.6701815","volume":"20","author":"DG Ezra","year":"2006","unstructured":"Ezra DG, Storoni M (2006) Whitefield LA (2006) Simultaneous bilateral acute angle closure glaucoma following venlafaxine treatment. Eye (Lond) 20(1):128\u2013129. https:\/\/doi.org\/10.1038\/sj.eye.6701815","journal-title":"Eye (Lond)"},{"issue":"4","key":"2396_CR12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3109\/08820538.2013.771193","volume":"28","author":"MA Sierra-Rodriguez","year":"2013","unstructured":"Sierra-Rodriguez MA, Saenz-Frances F, Santos-Bueso E, Garcia-Feijoo J, Gonzelez-Romero JC (2013) Chronic angle-closure glaucoma related to paroxetine treatment. Semin Ophthalmol 28(4):244\u2013246. https:\/\/doi.org\/10.3109\/08820538.2013.771193","journal-title":"Semin Ophthalmol"},{"issue":"5","key":"2396_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1471-2415-5-23","volume":"4","author":"R Croos","year":"2005","unstructured":"Croos R, Thirumalai S, Hassan S, Davis Jda R (2005) Citalopram associated with acute angle-closure glaucoma: case report. BMC Ophthalmol 4(5):23. https:\/\/doi.org\/10.1186\/1471-2415-5-23","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"2396_CR14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1089\/jop.2017.0133","volume":"34","author":"G U\u00e7an G\u00fcnd\u00fcz","year":"2018","unstructured":"U\u00e7an G\u00fcnd\u00fcz G, Parmak Yener N, K\u0131l\u0131n\u00e7el O, G\u00fcnd\u00fcz C (2018) How does usage of serotonin noradrenaline reuptake inhibitors affect intraocular pressure in depression patients? J Ocul Pharmacol Ther 34(4):354\u2013359. https:\/\/doi.org\/10.1089\/jop.2017.0133","journal-title":"J Ocul Pharmacol Ther"},{"issue":"45","key":"2396_CR15","doi-asserted-by":"publisher","first-page":"e2041","DOI":"10.1097\/MD.0000000000002041","volume":"94","author":"HY Chen","year":"2015","unstructured":"Chen HY, Lin CL, Kao CH (2015) Long-term use of selective serotonin reuptake inhibitors and risk of glaucoma in depression patients. Med (Baltimore) 94(45):e2041. https:\/\/doi.org\/10.1097\/MD.0000000000002041","journal-title":"Med (Baltimore)"},{"issue":"3","key":"2396_CR16","doi-asserted-by":"publisher","first-page":"e0173005","DOI":"10.1371\/journal.pone.0173005","volume":"12","author":"VC Chen","year":"2017","unstructured":"Chen VC, Ng MH, Chiu WC et al (2017) Effects of selective serotonin reuptake inhibitors on glaucoma: a nationwide population-based study. PLoS ONE 12(3):e0173005. https:\/\/doi.org\/10.1371\/journal.pone.0173005","journal-title":"PLoS ONE"},{"issue":"1","key":"2396_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1080\/15569527.2017.1330270","volume":"37","author":"GU G\u00fcnd\u00fcz","year":"2018","unstructured":"G\u00fcnd\u00fcz GU, Parmak Yener N, K\u0131l\u0131n\u00e7el O, G\u00fcnd\u00fcz C (2018) Effects of selective serotonin reuptake inhibitors on intraocular pressure and anterior segment parameters in open angle eyes. Cutan Ocul Toxicol 37(1):36\u201340. https:\/\/doi.org\/10.1080\/15569527.2017.1330270","journal-title":"Cutan Ocul Toxicol"},{"issue":"3","key":"2396_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00417-003-0785-7","volume":"242","author":"G Chidlow","year":"2014","unstructured":"Chidlow G, Hiscott PS, Osborne NN (2014) Expression of serotonin receptor mRNAs in human ciliary body: a polymerase chain reaction study. Graefes Arch Clin Exp Ophthalmol 242(3):259\u2013264. https:\/\/doi.org\/10.1007\/s00417-003-0785-7","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2396_CR19","first-page":"1040","volume":"12","author":"NA Sharif","year":"2006","unstructured":"Sharif NA, Senchyna M (2006) Serotonin receptor subtype mRNA expression in human ocular tissues, determined by RT-PCR. Mol Vis 12:1040\u20131047","journal-title":"Mol Vis"},{"issue":"3","key":"2396_CR20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.exer.2008.10.003","volume":"88","author":"NA Sharif","year":"2009","unstructured":"Sharif NA, McLaughlin MA, Kelly CR et al (2009) Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res 88(3):386\u2013397. https:\/\/doi.org\/10.1016\/j.exer.2008.10.003","journal-title":"Exp Eye Res"},{"key":"2396_CR21","doi-asserted-by":"publisher","first-page":"978","DOI":"10.2174\/138945010791591278","volume":"11","author":"NA Sharif","year":"2010","unstructured":"Sharif NA (2010) Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action. Curr Drug Targets 11:978\u2013993. https:\/\/doi.org\/10.2174\/138945010791591278","journal-title":"Curr Drug Targets"},{"key":"2396_CR22","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/003591577106400613","volume":"64","author":"ME Langham","year":"1971","unstructured":"Langham ME (1971) Role of adrenergic mechanisms in development and therapy of open-angled glaucoma. Proc Roy Soc Med 64:622\u2013628","journal-title":"Proc Roy Soc Med"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-022-02396-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-022-02396-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-022-02396-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T05:09:58Z","timestamp":1675660198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-022-02396-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["2396"],"URL":"https:\/\/doi.org\/10.1007\/s10792-022-02396-1","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"assertion":[{"value":"19 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest, or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the (Giresun University Clinical Research Ethics Committee) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}